These innovative compounds represent a significant leap in the therapy of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in lowering blood glucose levels. https://nanawpst102915.link4blogs.com/59935014/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide